

Advance-HTA Conference

19 November 2015

The Law Society – Common Room

(113 Chancery Lane London WC2A 1PL)

Agenda

- 09:00-09:20 Arrival and Registration
- 09:20-09:30 Welcome and Introduction: **Professor David Taylor**, Emeritus Professor, School of Pharmacy, (University College London)
- 09:30-09:45 Opening keynote: **Sofia Wallström**, Director General, Dental and Pharmaceutical Benefits Board (TLV), Sweden
- 09:45-10:00 *The Advance-HTA Partnership: from concept to delivery*, **Dr Panos Kanavos** (LSE)
- 10:00-11:00 Session 1: Assessing Value for Money: Health System Perspectives and Application to the Case of Orphan Drugs**
1. Why do some countries approve a cancer drug and others don't?, 10:00-10:15
Professor John Cairns (London School of Hygiene & Tropical Medicine)
 2. A comparative analysis of four countries in assessing orphan drugs, 10:15-10:30
Ms Elena Nicod (London School of Economics)
 3. Stakeholder Perspectives: 10:30-10:45
 - **Dr Karen Facey**, Evidence Based Health Policy Consultant
 - **Dr Josep Figueras**, Head, European Observatory on Health Systems and Policies
- Q&A session moderated by the chair 10:45-11:00
- 11:00-11:15 *Coffee Break*

11:15-12:15 **Session 2: New tools and approaches in the assessment of value of medical technologies**

- | | | |
|----|---|-------------|
| 4. | Multiple Criteria Decision Analysis in the context of HTA, Dr Panos Kanavos and Aris Angelis (<i>London School of Economics</i>) | 11:15-11:30 |
| 5. | HTA of medical devices: how to group them, how to evaluate them - current status and perspectives, Professor Reinhard Busse , <i>Technische Universität Berlin (TUB)</i> | 11:30-11:45 |
| 6. | Stakeholder Perspectives: | 11:45-12:00 |
| | <ul style="list-style-type: none"> • Annalisa Belloni, <i>Health Policy Analyst Organisation for Economic Co-operation & Development (OECD), Paris, France</i> • Hanne Bak Pedersen, <i>Programme Manager for Health Technologies & Pharmaceutical, World Health Organisation Europe, Copenhagen, Denmark</i> • Professor Guillem López Casanovas, <i>University Pompeu Fabra (UPF), Barcelona, Spain</i> | |
| | Q&A session moderated by the chair | 12:00-12:15 |

12:15-13:15 **Session 3: Preference Elicitation and Quality of Life**

- | | | |
|----|---|-------------|
| 7. | Whose preferences should we use in decision making in health care?, Valentina Rupel (<i>Institute of Economic Research, Ljubljana, Slovenia</i>) and Jean Mossman , <i>Policy Lead, European Brain Council</i> | 12:15-12:30 |
| 8. | Assessing the Societal Value in Rare Diseases by Decision Makers and Patients, Dr Julio Lopez-Bastida (<i>University of Castile-La Mancha</i>) | 12:30-12:45 |
| 9. | Stakeholder Perspectives: | 12:45-13:00 |
| | <ul style="list-style-type: none"> • Jean Mossman, <i>Policy Lead, European Brain Council</i> • Bettina Ryll, MD/PhD <i>Founder, Melanoma Patient Network Europe</i> • Dr Karen Facey, <i>Evidence Based Health Policy Consultant</i> | |
| | Q&A session moderated by the chair | 13:00-13:15 |

13:15-14:15 *Lunch*

14:15-15:15 **Session 4: Strengthening and Implementing HTA in Emerging Settings**

10. HTA in Emerging Settings – Mapping Exercise and Toolbox, **Prof Jaime Espin**, *Escuela Andaluza de Salud Publica, Grenada, Spain (EASP)* 14:15-14:30
11. The Importance of HTA in Emerging Settings - The REDE TSA Experience, **Dr Alexandre Lemgruber**, *Pan-American Health Organisation (PAHO)* 14:30-14:45
12. Stakeholder Perspectives: 14:45-15:00
- **Guillaume Dedet**, *World Health Organisation Europe, Copenhagen, Denmark*
 - **Francis Ruiz**, *NICE International, UK*

Q&A session moderated by the chair 15:00-15:15

15:15-15:30 *Coffee break*

15:30-16:40 **Session 5: HTA and the future: Stakeholder Reflections (Chair: Dr Panos Kanavos)**

13. **Anna Zawada**, *Head of Division of Health Care Programmes, Agency for Health Technology Assessment and Tariff System, Poland* 15:30-15:55
14. **Douglas Lundin**, *Chief Economist, TLV, Sweden*
15. **Francis Ruiz**, *NICE International, UK*
16. **Prof Finn Borlum Kristensen**, *Chairman, Executive Committee of the European Network for Health Technology Assessment (EUnetHTA)*
17. **Dr Mary Baker**, *President, European Brain Council* 15:55-16:05
18. **Prof Daniel Hochhauser**, *University College London (UCL)* 16:05-16:15

Q&A 16:15-16:40

16:40-16:50 **Session 6: Lessons Learnt and Future Directions**

Dr Panos Kanavos (LSE)

Conference Ends